1 March 2003 in The Journal of Pharmacology and Experimental Therapeutics
We tested the hypothesis that pyridostigmine bromide (PB) intake and/or low-level sarin exposure, suggested by some as causes of the symptoms experienced by Persian Gulf War veterans, induce neurobehavioral dysfunction that outlasts their effects on cholinesterase. Adult male Sprague-Dawley rats were treated during 3 weeks with s.c. saline, PB in drinking water (80 mg/l), sarin (62.5 μg/kg; 0.5× LD50, three times/week s.c.), or PB in drinking water + sarin. Animals were tested for passive avoidance, nociceptive threshold, acoustic startle, and open field activity 2, 4, or 16 weeks after treatment. Two weeks after sarin, acoustic startle was enhanced, whereas distance explored in the open field decreased. These effects were absent with PB + sarin or PB by itself. No effect on any variable was found at 4 weeks, whereas at 16 weeks sarin induced a decrease and PB + sarin induced an increase in habituation in the open field test. Nociceptive threshold was elevated in the PB + sarin group at 16 weeks. No effect of treatment on passive avoidance was noted in any group. Brain regional acetylcholinesterase and cholineacetyltransferase activities were not affected at any time after treatment, but muscarinic receptors were down-regulated in hippocampus, caudate putamen, and mesencephalon in the sarin group at 2 weeks. In conclusion, this study gives further support to the use of PB against nerve agent poisoning and does not support the hypothesis that delayed symptoms experienced by Persian Gulf War veterans could be due to PB, alone or in association with low-level sarin exposure.
1 December 2014 in NeuroToxicology
1 September 2000 in Hypertension
Abstract —Polymorphic variants of the cytoskeletal protein adducin have been associated with hypertension in humans and rats. However, the direct role of this protein in modulating arterial blood pressure has never been demonstrated. To assess the effect of β-adducin on blood pressure, a β-adducin–deficient mouse strain (−/−) was studied and compared with wild-type controls (+/+). Aortic blood pressure was measured in nonanesthetized, freely moving animals with the use of telemetry implants. It is important to note that these mice have at least 98% of C57Bl/6 genetic background, with the only difference from wild-type animals being the β-adducin mutation. We found statistically significant higher levels of systolic blood pressure (mm Hg) (mean±SE values: −/−: 126.94±1.14, n=5; +/+: 108.06±2.34, n=6; P ≤0.0001), diastolic blood pressure (−/−: 83.54±1.07; +/+: 74.87±2.23; P ≤0.005), and pulse blood pressure (−/−: 43.32±1.10; +/+: 33.19±1.96; P ≤0.001) in β-adducin–deficient mice. Western blot analysis showed that as a result of the introduced genetic modification, β-adducin was not present in heart protein extracts from −/− mice. Consequently, this deficiency produced a sharp decrease of α-adducin and a lesser reduction in γ-adducin levels. However, we found neither cardiac remodeling nor modification of the heart function in these animals. This is the first report showing direct evidence that hypertension is triggered by a mutation in the adducin gene family.
8 December 2006 in Brain Research
1 April 1999 in Brain Research
1 August 2015 in Neuroscience